Relationship Between 8-iso-prostaglandin-F<sub>2α</sub> and Predicted 10-Year Cardiovascular Risk in Hypertensive Patients
Giulio Geraci,
Alessandra Sorce,
Luca Zanoli,
Giuseppe Cuttone,
Vincenzo Calabrese,
Francesco Pallotti,
Valentina Paternò,
Pietro Ferrara,
Ligia J. Dominguez,
Riccardo Polosa,
Jacob George,
Giuseppe Mulè,
Caterina Carollo
Affiliations
Giulio Geraci
Department of Medicine and Surgery, Kore University of Enna, 94100 Enna, Italy
Alessandra Sorce
Unit of Nephrology and Dialysis, Hypertension Excellence Centre, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, 90133 Palermo, Italy
Luca Zanoli
Nephrology, Department of Clinical and Experimental Medicine, University of Catania, 95124 Catania, Italy
Giuseppe Cuttone
Department of Medicine and Surgery, Kore University of Enna, 94100 Enna, Italy
Vincenzo Calabrese
Department of Medicine and Surgery, Kore University of Enna, 94100 Enna, Italy
Francesco Pallotti
Department of Medicine and Surgery, Kore University of Enna, 94100 Enna, Italy
Valentina Paternò
Operative Unit of Diabetology, Umberto I Hospital, Provincial Health Authority (ASP) of Enna, 94100 Enna, Italy
Pietro Ferrara
Center for Public Health Research, University of Milan–Bicocca, 20900 Monza, Italy
Ligia J. Dominguez
Department of Medicine and Surgery, Kore University of Enna, 94100 Enna, Italy
Riccardo Polosa
Department of Medicine and Surgery, Kore University of Enna, 94100 Enna, Italy
Jacob George
Cardiovascular Medicine and Therapeutics, University of Dundee Medical School, Ninewells Hospital, Dundee DD1 9SY, UK
Giuseppe Mulè
Unit of Nephrology and Dialysis, Hypertension Excellence Centre, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, 90133 Palermo, Italy
Caterina Carollo
Unit of Nephrology and Dialysis, Hypertension Excellence Centre, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, 90133 Palermo, Italy
Background: 8-iso-prostaglandin-F2α (8-iso-PGF2α) is a recognized marker of oxidative stress. Previous studies suggested that 8-iso-PGF2α plays an important role in the pathogenesis of hypertension and cardiovascular (CV) diseases. However, limited data exist on the prognostic role of 8-iso-PGF2α in hypertensive patients undergoing primary prevention. The aim of this study was to assess the relationship between 8-iso-PGF2α and 10-year CV risk, as predicted by validated equations in hypertension patients without CV diseases. Materials and methods: A total of 432 individuals aged 40–75 years were enrolled. Plasma 8-iso-PGF2α was assessed through the ELISA method. CV risk was calculated by using the Framingham Risk Score (Fr-S) and the Atherosclerosis Cardiovascular Disease Risk Score (ASCVD-S). Low, moderate, or high CV risks were defined according to validated cutoffs. Results: Individuals with higher CV risk had significantly greater 8-iso-PGF2α values compared to those with low or moderate CV risk (p 2α correlated strongly with Fr-S and ASCVD-S in the entire population and in patients with normal renal function (all p 2. These associations remained significant after adjustment for traditional factors included in the CV risk equations in the overall population and in patients with normal renal function. The 8-iso-PGF2α cutoffs that best distinguished patients with high CV risk were 310 pg/mL for Fr-S and 264 pg/mL for ASCVD-S in the overall population, with significant differences between the groups divided by eGFR (all p 2α as a biomarker for refining cardiovascular risk stratification in hypertensive patients, particularly those with preserved renal function. Future studies should explore its prognostic value in longitudinal cohorts and assess its integration into clinical risk models to enhance early prevention strategies for cardiovascular disease.
